Mayank Mamtani - B. Riley Financial
Mr. Mamtani has been one of the leading voices on the Street in prophylactic innovations for cardiovascular and infectious diseases, both aimed at reducing significant burden on global healthcare systems. Individually, was ranked within 1% among thousands of …
Mayank Mamtani - B. Riley Securities - LinkedIn
View Mayank Mamtani’s profile on LinkedIn, a professional community of 1 billion members. Mayank serves as managing director, group head of healthcare research for B. Riley…
- 500+ connections
- Location: B. Riley Securities
Mayank Mamtani - Analyst at B. Riley Securities - Stock Analysis
Jan 8, 2025 · Mayank Mamtani is a Wall Street analyst working for B. Riley Securities. Mayank has covered 32 stocks with a 43.27% success rate and an average return of 36.35%.
B. Riley Strengthens Position as Leading Small- and Mid-Cap …
Jul 28, 2020 · Mayank Mamtani was promoted to Senior Analyst and Group Head of Healthcare Research. He joined B. Riley as a Research Analyst in 2018 and covers biotechnology companies pioneering cutting-edge therapeutics innovation in liver diseases, hematology-oncology, and infectious diseases.
Maintained Buy Rating for Lineage Cell Therapeutics on Robust …
May 6, 2024 · Mayank Mamtani has given his Buy rating due to a combination of factors, including the strength of recent clinical trial results for Lineage Cell Therapeutics.
Strategic Transformation and Growth Prospects: Mayank Mamtani…
Nov 18, 2024 · B.Riley Financial analyst Mayank Mamtani has maintained their bullish stance on NVAX stock, giving a Buy rating on November 13. Mayank Mamtani’s rating is based on several strategic and...
B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)
3 days ago · B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of $20.00. The company’s shares closed yesterday at $7.00 ...
Sorrento: Breaking Down B. Riley’s New Bullish Call - Yahoo …
Feb 1, 2021 · Diversifying a portfolio is often cited as a safe investing strategy, but it is also the game plan adopted by Sorrento Therapeutics (SRNE). This varied approach could provide investors with some...
Mayank Mamtani | Analyst | Madrigal Pharmaceuticals.
Mayank Mamtani B Riley FBR . Madrigal’s ambitious research programs led to the first FDA-approved treatment in NASH. Learn More. Madrigal Pharmaceuticals. 200 Barr Harbor Drive, Suite 200. West Conshohocken, Pennsylvania 19428. About Us; Our Programs; NASH; Investors & Media; Careers; Contact;
This Analyst Says to Be Positive About Novavax’s Covid ... - Nasdaq
May 3, 2022 · Riley analyst Mayank Mamtani published some "quick thoughts" on this latest development and its implications for Novavax stock.